APLE vs CURB

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score, limiting bankruptcy risk assessment. Despite a seemingly attractive valuation with a Price/Book below 1 and a 7.7% dividend yield, the company faces declining earnings and revenue, a high payout ratio of 129.73%, and weakening profitability trends. Analysts recommend a buy, but recent earnings misses, deteriorating growth, and lack of insider buying undermine confidence. The stock trades above the Graham Number ($14.87) but well above its intrinsic value estimate of $5.11, suggesting overvaluation relative to fundamentals.

CURB exhibits a severe valuation disconnect, trading at $28.10 despite a Graham Number of $12.28 and an Intrinsic Value of $2.59. While the Piotroski F-Score of 4/9 indicates stable health, this is overshadowed by a catastrophic dividend payout ratio of 172.97%, suggesting the dividend is unsustainable. Revenue growth is purely inorganic (driven by acquisitions), while actual earnings are contracting (-10.2% YoY). Combined with bearish insider activity from the CEO and a P/E ratio of 75.95, the stock appears significantly overvalued.